Skip to main content

Tofacitinib, Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and Tumor Necrosis Factor Inhibitors (TNFi) Use: A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
disease-modifying anti-rheumatic drugs (DMARDs)
tofacitinib
tumor necrosis factor inhibitors (TNFi)
Description

In this report we examined characteristics of patients receiving disease-modifying anti-rheumatic drugs (DMARDs), tumor necrosis factor inhibitors (TNFi), or tofacitinib in the Sentinel Distributed Database (SDD) along with switching patterns observed between these exposures.

The study period includes data from November 1, 2012 to September 30, 2019. We distributed this request to 16 Sentinel Data Partners on February 25, 2020.

Deliverables (1)
Sentinel Modular Program Report: Tofacitinib, Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and Tumor Necrosis Factor Inhibitors (TNFi) Use: A Descriptive Analysis
Additional Details
FDA Center
CDER
Time Period
November 1, 2012 - September 30, 2019
Analysis Type
Descriptive
Population / Cohort
Individuals 18 years of age and older
Data Sources
Sentinel Distributed Database (SDD)